Helix BioPharma Corp.

As of April 30, 2026, Helix BioPharma Corp. carries a market capitalization of 151.23M, placing it among publicly traded companies globally. Its enterprise value stands at 148.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Helix BioPharma Corp.'s next confirmed earnings release is scheduled for November 4, 2026.

As of April 30, 2026, Helix BioPharma Corp. has 76.38M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, Helix BioPharma Corp. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026.

As of the close on October 22, 2026, Helix BioPharma Corp.'s stock has declined approximately 59.17% over the past 52 weeks. The 50-day moving average sits at 1.42, while the 200-day moving average is 1.72.

As of April 30, 2026, Helix BioPharma Corp. holds 2.84M in cash and equivalents against 359,000.00 in total debt, resulting in a net debt position of -2.48M. Total book value stands at 14.69M, with working capital of -3.70M providing operational flexibility.

Helix BioPharma Corp.'s most recent stock split took place on August 16, 2024 with a 5:1 split ratio.